Terms: = Leukemia AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
1 results:
1. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Ragon BK; Kantarjian H; Jabbour E; Ravandi F; Cortes J; Borthakur G; DeBose L; Zeng Z; Schneider H; Pemmaraju N; Garcia-Manero G; Kornblau S; Wierda W; Burger J; DiNardo CD; Andreeff M; Konopleva M; Daver N
Am J Hematol; 2017 Jan; 92(1):7-11. PubMed ID: 27673440
[TBL] [Abstract] [Full Text] [Related]
